ATE486940T1 - Abgeschwächte salmonella sp12 mutante als antigen-träger. - Google Patents

Abgeschwächte salmonella sp12 mutante als antigen-träger.

Info

Publication number
ATE486940T1
ATE486940T1 AT08075560T AT08075560T ATE486940T1 AT E486940 T1 ATE486940 T1 AT E486940T1 AT 08075560 T AT08075560 T AT 08075560T AT 08075560 T AT08075560 T AT 08075560T AT E486940 T1 ATE486940 T1 AT E486940T1
Authority
AT
Austria
Prior art keywords
cell
nucleic acid
acid molecule
antigen
carrier
Prior art date
Application number
AT08075560T
Other languages
English (en)
Inventor
Michael Hensel
Carlos Alberto Guzman
Eva Medina
Heiko Apfel
Christoph Hueck
David William Holden
Jacqueline Elizabeth Shea
Original Assignee
Emergent Product Dev Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Product Dev Uk Ltd filed Critical Emergent Product Dev Uk Ltd
Application granted granted Critical
Publication of ATE486940T1 publication Critical patent/ATE486940T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT08075560T 1998-09-04 1999-09-03 Abgeschwächte salmonella sp12 mutante als antigen-träger. ATE486940T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98116827 1998-09-04

Publications (1)

Publication Number Publication Date
ATE486940T1 true ATE486940T1 (de) 2010-11-15

Family

ID=8232583

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08075560T ATE486940T1 (de) 1998-09-04 1999-09-03 Abgeschwächte salmonella sp12 mutante als antigen-träger.
AT99946122T ATE403728T1 (de) 1998-09-04 1999-09-03 Attenuierte salmonella spi2 mutante als antigen- träger

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT99946122T ATE403728T1 (de) 1998-09-04 1999-09-03 Attenuierte salmonella spi2 mutante als antigen- träger

Country Status (13)

Country Link
US (3) US6936425B1 (de)
EP (2) EP1108034B1 (de)
JP (1) JP2002524077A (de)
AT (2) ATE486940T1 (de)
AU (1) AU5860599A (de)
BR (1) BR9914479A (de)
CA (1) CA2341349C (de)
CY (1) CY1109387T1 (de)
DE (2) DE69939264D1 (de)
DK (1) DK1108034T3 (de)
ES (2) ES2356863T3 (de)
PT (1) PT1108034E (de)
WO (1) WO2000014240A2 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69526377T2 (de) * 1994-12-09 2002-11-07 Microscience Ltd Virulenzgene in der VGC2-Region von Salmonella
ATE486940T1 (de) * 1998-09-04 2010-11-15 Emergent Product Dev Uk Ltd Abgeschwächte salmonella sp12 mutante als antigen-träger.
AU2003204710B2 (en) * 1999-05-10 2006-08-03 Microscience Limited Attenuated microorganisms for the treatment of infection
GB9910812D0 (en) 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
EP1640013A3 (de) * 2000-03-17 2007-02-21 Pharmacia & Upjohn Company LLC Inaktivierte Salmonella Impfstoffe
AU2001256957B2 (en) 2000-03-17 2005-08-25 Pharmacia & Upjohn Company Llc Salmonella vaccine materials and methods
GB0105924D0 (en) * 2001-03-09 2001-04-25 Microscience Ltd Promoter
ATE345386T1 (de) * 2001-05-17 2006-12-15 Creatogen Ag Methode zum auffinden von abgeschwächten oder virulent-defekten mikroben
WO2006015445A1 (en) 2004-08-13 2006-02-16 Marshall Barry J Bacterial delivery system
US8029777B2 (en) 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
RU2296560C2 (ru) * 2004-08-25 2007-04-10 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потебителей и благополучия человека (ФГУН ГНЦ ВБ "ВЕКТОР" Роспотребнадзора) Суппозитории для иммунопрофилактики вирусных инфекций
CN1276076C (zh) * 2004-12-14 2006-09-20 华东理工大学 一种鳗弧菌野生毒株的无标记基因缺失减毒突变株及其应用
US20070134814A1 (en) * 2005-12-09 2007-06-14 Kajander E O Methods and compositions for the detection of calcifying nano-particles, identification and quantification of associated proteins thereon, and correlation to disease
EP2517723B1 (de) * 2006-09-18 2019-11-06 The Board of Trustees of The University of Arkansas Zusammensetzungen und Verfahren zur Verstärkung von Immunreaktionen
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
EP2152883A4 (de) * 2007-05-10 2010-10-27 Univ Arizona Rekombinante bakterien mit vektoren zur expression von nukleinsäuresequenzencodierenden antigenen
WO2009025888A2 (en) 2007-05-10 2009-02-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety
WO2008153772A2 (en) * 2007-05-25 2008-12-18 Emergent Product Development Gaithersburg Inc. Chlamydia vaccine comprising htra polypeptides
WO2009046449A1 (en) * 2007-10-05 2009-04-09 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
CA2704457A1 (en) * 2007-10-30 2009-05-07 Walter Bottje Compositions and methods of enhancing immune responses to flagellated bacterium
NZ585777A (en) 2007-11-01 2012-09-28 Univ Arkansas Compositions and methods of enhancing immune responses to eimeria
RU2392003C2 (ru) * 2008-04-02 2010-06-20 ФГОУ ВПО Курская государственная сельскохозяйственная академия им. профессора И.И. Иванова Способ получения сальмонеллезной вакцины
EP2326344A4 (de) 2008-06-16 2013-08-07 Prokarium Ltd Impfstoffe mit salmonellen-vektor gegen chlamydien und anwendungsverfahren
WO2010017383A1 (en) 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
WO2010045620A1 (en) 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
US20120064114A1 (en) * 2008-10-21 2012-03-15 Emergent Product Development United Kingdom Use of e. coli surface antigen 3 sequences for the export of heterologous antigens
JP4575498B2 (ja) * 2009-02-20 2010-11-04 株式会社東芝 磁気記録媒体の製造方法
US9163219B2 (en) * 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
WO2010141143A2 (en) * 2009-04-21 2010-12-09 Vivocure, Inc. Engineered avirulent bacteria strains and use in medical treatments
US8518658B1 (en) * 2009-04-27 2013-08-27 University Of South Florida ATP-bioluminescence immunoassay
GB2483595B (en) * 2009-05-22 2017-03-29 The Arizona Board Of Regents For And On Behalf Of Arizona State Univ Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) * 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
NZ601609A (en) 2010-01-21 2014-08-29 Univ Arkansas Vaccine vectors and methods of enhancing immune responses
EP2526185A4 (de) 2010-01-22 2013-07-24 Univ Arizona Bakterium mit einer regulierten rfah-nukleinsäure
US9598697B2 (en) 2010-05-28 2017-03-21 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
AU2011264772B2 (en) 2010-06-09 2015-07-16 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce Campylobacter infection
US8481052B2 (en) 2011-05-17 2013-07-09 Cj Cheiljedang Corporation Avirulent Salmonella gallinarum variants and pharmaceutical composition using the same
RU2510839C2 (ru) * 2012-05-03 2014-04-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" Вакцина ассоциированная против сальмонеллеза, эшерихиоза и вирусной геморрагической болезни кроликов
RU2496518C1 (ru) * 2012-05-03 2013-10-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" Способ изготовления вакцины ассоциированной против сальмонеллеза, эшерихиоза и вирусной геморрагической болезни кроликов
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
CN104470537B (zh) * 2012-05-23 2017-04-26 美国政府(由卫生和人类服务部的部长所代表) 表达鼠疫耶尔森氏菌F1‑V融合蛋白的伤寒沙门氏菌Ty21a及其用途
ES2752190T3 (es) 2012-09-14 2020-04-03 Us Health Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso
US9603915B2 (en) 2013-02-14 2017-03-28 The Board of Trustees of the University of Akansas Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection
KR102239207B1 (ko) 2013-03-15 2021-04-09 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 장내 병원균에 대한 면역 반응을 증진시키는 조성물 및 방법
US9636386B2 (en) * 2013-03-15 2017-05-02 City Of Hope Attenuated Salmonella bacteria and methods of using
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof
US10987432B2 (en) * 2013-09-05 2021-04-27 The University Of Hong Kong Therapeutic delivery and expression system, methods and uses thereof
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
TWI843057B (zh) 2016-05-03 2024-05-21 阿肯色州大學董事會 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
WO2021076897A1 (en) * 2019-10-18 2021-04-22 University Of Virginia Patent Foundation Compositions and methods for producing enhanced immune responses and rapid antibody production
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
GB202019767D0 (en) 2020-12-15 2021-01-27 Chain Biotechnology Ltd Compostitions and methods
WO2022271976A1 (en) * 2021-06-24 2022-12-29 Elanco Us Inc. Attenuated salmonella, vaccines, and delivery platform
CN114292339B (zh) * 2022-01-05 2022-08-09 武汉科前生物股份有限公司 鞭毛素突变体与非洲猪瘟抗原的融合蛋白及其应用
CN114703214A (zh) * 2022-03-03 2022-07-05 南京吉芮康生物科技研究院有限公司 一种抗丢失时空可控表达的新型质粒及其应用
EP4590831A1 (de) * 2022-09-21 2025-07-30 Prokarium Limited Salmonellastamm mit chromosomal integriertem landepad

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US232165A (en) * 1880-09-14 Mechanical musical instrument
US1449502A (en) * 1921-04-23 1923-03-27 James G Diffendaffer Restraining device
US1476164A (en) * 1922-02-21 1923-12-04 Michael J Manahan Door and window shade and curtain clamp
US1903387A (en) * 1930-08-20 1933-04-04 Eaton Mfg Co Automobile heater
US2103863A (en) * 1936-12-28 1937-12-28 Woodall Industries Inc Visor construction
US2728467A (en) * 1954-01-28 1955-12-27 Glicker Herman Parking tower structure
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
LU88258I2 (de) 1978-12-22 1994-02-03
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US5210035A (en) 1980-05-19 1993-05-11 Board Of Trustees Of Leland Stanford Jr. University Non-reventing live vaccines
US4837151A (en) 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US4550081A (en) 1980-05-19 1985-10-29 The Board Of Trustees Of The Leland Stanford Jr. University Non-reverting salmonella
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US5643579A (en) 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US5397697A (en) 1989-01-10 1995-03-14 Ciba-Geigy Corporation Identification of plant-responsive genes of bacteria
FR2664614B1 (fr) 1990-07-11 1992-10-16 Pasteur Institut Sequences nucleiques issues du genome de salmonella typhi, et leurs utilisations notamment pour le diagnostic in vitro de la presence de bacteries du genre salmonella dans les produits alimentaires.
SE9101433D0 (sv) 1991-05-13 1991-05-13 Marianne Hansson Recombinant dna sequence and its use
AU2509592A (en) 1991-08-22 1993-03-16 Washington University Polynucleotide probes for salmonella
WO1993007266A1 (en) 1991-10-07 1993-04-15 Idaho Research Foundation, Inc. Genetic construct for selection of homologous recombinants on a single selective medium
US5356797A (en) 1991-11-15 1994-10-18 Board Of Regents, The University Of Texas Membrane expression of heterologous genes
AU3130893A (en) 1991-11-15 1993-06-15 Board Of Regents, The University Of Texas System Membrane expression of heterologous genes
CA2148829A1 (en) 1992-11-06 1994-05-26 Keum Hwa Choi Avirulent live vaccine and method for immunizing animals against p. multocida pasteurellosis
WO1994026933A1 (en) 1993-05-13 1994-11-24 The Board Of Trustees Of The Leland Stanford Junior University Genetic footprinting: insertional mutagenesis and genetic selection
AU3958895A (en) 1994-10-18 1996-05-06 Board Of Regents, The University Of Texas System Membrane expression of heterologous genes
DE69526377T2 (de) 1994-12-09 2002-11-07 Microscience Ltd Virulenzgene in der VGC2-Region von Salmonella
US5700683A (en) 1995-02-17 1997-12-23 Pathogenesis Corporation Virulence-attenuating genetic deletions deleted from mycobacterium BCG
WO1997014800A1 (en) 1995-10-16 1997-04-24 Smithkline Beecham Plc Novel saliva binding protein
AU7738396A (en) 1995-11-14 1997-06-05 General Hospital Corporation, The Salmonella secreted proteins and uses thereof
US6030624A (en) 1996-08-16 2000-02-29 Uab Research Foundation Mucosal immunogens for novel vaccines
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
EP1017283B1 (de) 1997-02-14 2004-12-15 Merck & Co., Inc. Polynukleotid-impfstoff-formulierungen
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
GB9804809D0 (en) 1998-03-06 1998-04-29 Wallis Timothy S Attenuated salmonella:materials and methods relating thereto
US6585975B1 (en) 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
ATE486940T1 (de) 1998-09-04 2010-11-15 Emergent Product Dev Uk Ltd Abgeschwächte salmonella sp12 mutante als antigen-träger.
US6846667B1 (en) 1998-11-09 2005-01-25 Microscience, Ltd. Virulence genes and proteins, and their use
GB9910812D0 (en) 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
WO2001032697A2 (en) 1999-11-05 2001-05-10 L'unite De Recherche En Biologie Moleculaire (Urbm) Des Facultes Universitaires Notre Dame De La Paix (Fundp) Virulence genes and proteins from brucella melitensis, and their use
AU775385B2 (en) 1999-12-23 2004-07-29 Microscience Limited Virulence genes, proteins, and their use
GB0011108D0 (en) 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
GB0127657D0 (en) 2001-11-19 2002-01-09 Microscience Ltd Virulence genes and proteins and their use
US7449178B2 (en) 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria

Also Published As

Publication number Publication date
DK1108034T3 (da) 2008-11-10
AU5860599A (en) 2000-03-27
US7700104B2 (en) 2010-04-20
US6936425B1 (en) 2005-08-30
DE69939264D1 (de) 2008-09-18
WO2000014240A2 (en) 2000-03-16
EP1108034A2 (de) 2001-06-20
EP1108034B1 (de) 2008-08-06
WO2000014240A3 (en) 2000-08-03
ES2356863T3 (es) 2011-04-13
US20080075739A1 (en) 2008-03-27
CA2341349A1 (en) 2000-03-16
ES2313792T3 (es) 2009-03-01
US7955600B2 (en) 2011-06-07
JP2002524077A (ja) 2002-08-06
PT1108034E (pt) 2008-11-14
EP1970449B1 (de) 2010-11-03
EP1970449A1 (de) 2008-09-17
US20040203039A1 (en) 2004-10-14
BR9914479A (pt) 2001-06-26
CA2341349C (en) 2013-12-10
ATE403728T1 (de) 2008-08-15
CY1109387T1 (el) 2014-07-02
DE69942925D1 (de) 2010-12-16

Similar Documents

Publication Publication Date Title
ATE486940T1 (de) Abgeschwächte salmonella sp12 mutante als antigen-träger.
NZ618298A (en) A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
DE69536039D1 (de) Wirtszelle enthaltend ein rekombinantes Virus, welches ein Antigen exprimiert und ein rekombinantes Virus, welches ein immunstimulatorisches Molekül exprimiert
ATE219948T1 (de) Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten
HUP0301659A2 (hu) Kukorica cellulóz-szintetázok és alkalmazásuk
KR937000640A (ko) 생 백신
EP0837928A4 (de) Zusammensetzungen aus rekombinierten poxvirus-cytomegalovirus und ihre verwendung
NO960839L (no) Bakterieeksporterte proteiner og acellulære vaksiner som er basert på disse
CY1107656T1 (el) Εξασθενημενοι μικροοργανισμοι για την αντιμετωπιση μολυνσης
ATE401406T1 (de) Hühner-anaemie-virus mutante, impfstoffe, und verwendungen basiert auf virusprotein vp3, oder dafür kodierende virus-sequenzen
DK0892054T3 (da) Clostridium perfringens-vaccine
AU2529095A (en) Vaccine against mycobacterial infections
AU3532089A (en) A pasteurella vaccine
Roberts et al. Comparison of abilities of Salmonella enterica serovar typhimurium aroA aroD and aroA htrA mutants to act as live vectors
WO2001012657A3 (en) Methods and means for selenoprotein expression
DK0499681T3 (da) pCTD-plasmid isoleret fra Chlamydia trachomatis serotype D, dets gener og proteiner, som kodes af dem; rekombinante plasmid
Kamei et al. Induction of stress protein synthesis in Histoplasma capsulatum by heat, low pH and hydrogen peroxide
DE69941099D1 (de) Spezifische Nukleinsäuren und Polypeptide aus krankheitserregenden Stämmen von Neisseria
IT1317849B1 (it) Mezzi e metodi per l'espressione di proteine omologhe ed eterologhe inceppi di rhodococcus.
PT729509E (pt) Vacina contra papeira contendo uma estirpe do virus jerryl-lynn
DK230890A (da) Dna-fragment, der koder for et pasteurella multocida-toxin eller for en subsekvens eller analog deraf, ekspressionsvektor, der omfatter dna-fragmentet, mikroorganisme, der udtrykker dette, fremgangsmaade til fremstilling af et pasteurella-multocida-toxin, diagnostisk middel samt anvendelse heraf, vaccine indeholdende et pasteurella-multocida-toxinderivat, anvendelse af pasteurella multocida-t m.m.
EA200000618A1 (ru) Вакцина для иммунизации позвоночных против заболеваний, вызываемых патогеном, вакцина для профилактики или лечения позвоночного от бруцеллеза, аттенюированный или авирулентный вариант штамма в. abortus rb51, способ профилактики или лечения позвоночного при риске заболевания или страдающего от патогенного микроорганизма (варианты), способ профилактики или лечения позвоночного при риске заболевания или страдающего от бруцеллеза
WO1996002272A3 (en) Treatment of autoimmune diseases
UA25234A (uk) Спосіб профілактики колібактеріозу твариh
PT663955E (pt) Acido nucleico que codifica para uma alfa-acetolactato-descarboxilase e suas aplicacoes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties